Pulmonary Pharmacology

Pulmonary Pharmacology, Volume 98 provides in-depth reviews on respiratory drug discovery and development, including corticosteroids, monoclonal antibodies, tyrosine kinase inhibitors, and phosphodiesterase inhibitors, as well as senotherapy and novel pulmonary delivery technologies.

Format: Hardback
Length: 312 pages
Publication date: 01 August 2023
Publisher: Elsevier Science Publishing Co Inc

Pulmonary Pharmacology, Volume 98, is a comprehensive resource that delves into the latest advancements in respiratory drug discovery and development. This esteemed volume encompasses a wide range of topics, including corticosteroids, monoclonal antibodies, tyrosine kinase inhibitors, and phosphodiesterase inhibitors, which are employed in the treatment of asthma, COPD, and pulmonary fibrosis. Furthermore, it explores innovative therapeutic approaches such as renin-angiotensin system modulators, mitochondrial function modulators, and non-antibacterial macrolides. Additionally, the book dedicates a significant portion to senotherapy for lung aging in respiratory diseases and explores novel pulmonary delivery technologies, including inhaled biologics.

The editors of this publication have assembled a team of renowned experts in the field, ensuring that the content is both authoritative and up-to-date. Each review provides a detailed analysis of the latest research findings, while also offering insights into the clinical implications and future directions of these therapeutic agents.

Pulmonary Pharmacology, Volume 98, is an invaluable resource for researchers, physicians, and pharmaceutical professionals engaged in the study and treatment of respiratory diseases. It offers a comprehensive overview of the current state-of-the-art in respiratory drug discovery and development, and serves as a valuable guide for those seeking to stay informed about the latest advancements in this field.

Weight: 450g
Dimension: 229 x 151 (mm)
ISBN-13: 9780443188800